Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma

Annals of Oncology

Volumn 24, Issue 8, 2013, Pages 2113-2118

  Maraldo, M V ^a   Brodin, N P ^a,b   Aznar, M C ^a   Vogelius, I R ^a   Munck af Rosenschold P ^a,b   Petersen, P M ^a   Specht, L ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cardiovascular disease; Highly conformal radiotherapy; Hodgkin lymphoma; Involved node radiotherapy; Secondary cancers

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DOSIMETRY; FEMALE; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; MALE; MANTLE FIELD RADIOTHERAPY; METASTASIS; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PHOTON THERAPY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIOTHERAPY; RISK ASSESSMENT; RISK FACTOR; THREE DIMENSIONAL CONFORMAL RADIOTHERAPY; VOLUMETRIC MODULATED ARC THERAPY;

CARDIOVASCULAR DISEASE; HIGHLY CONFORMAL RADIOTHERAPY; HODGKIN LYMPHOMA; INVOLVED NODE RADIOTHERAPY; SECONDARY CANCERS;

ADOLESCENT; ADULT; AGED; BREAST; CARDIOVASCULAR DISEASES; FEMALE; HEART; HODGKIN DISEASE; HUMANS; LUNG; LYMPHATIC IRRADIATION; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; ORGANS AT RISK; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RISK; YOUNG ADULT;

EID: 84881239116     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt156     Document Type: Article

References (24)

1. Herbst C, Rehan FA, Brillant C et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. Haematologica 2010; 95: 494-500.
2. Aleman BM, van den Belt-Dusebout AW, De Bruin ML et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007; 109: 1878-1886.
3. Ng AK, Bernardo MP, Weller E et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002; 20: 2101-2108.
4. Ng AK, Bernardo MV, Weller E et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002; 100: 1989-1996.
5. Travis LB, Gospodarowicz M, Curtis RE et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002; 94: 182-192.
6. Travis LB, Hill DA, Dores GM et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003; 290: 465-475.
7. Eich HT, Diehl V, Gorgen H et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010; 28: 4199-4206.
8. Engert A, Plutschow A, Eich HT et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363: 640-652.
9. Maraldo MV, Aznar MC, Vogelius IR et al Involved node radiation therapy: an effective Alternative in Early-Stage Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys 2013; 85: 1057-1065.
10. Paumier A, Ghalibafian M, Beaudre A et al. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2011; 80: 199-205.
11. Campbell BA, Hornby C, Cunninghame J et al. Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy. Ann Oncol 2012; 23: 1259-1266.
12. Fiandra C, Filippi AR, Catuzzo P et al. Different IMRT solutions vs 3D-conformal radiotherapy in early stage Hodgkin's lymphoma: dosimetric comparison and clinical considerations. Radiat Oncol 2012; 7: 186.
13. Koeck J, Abo-Madyan Y, Lohr F et al. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy. Int J Radiat Oncol Biol Phys 2012; 83: 268-276.
14. Weber DC, Peguret N, Dipasquale G et al. Involved-node and involved-field volumetric modulated arc vs fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study. Int J Radiat Oncol Biol Phys 2009; 75: 1578-1586.
15. Hoppe BS, Flampouri S, Su Z et al. Consolidative involved-node proton therapy for stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a phase II study. Int J Radiat Oncol Biol Phys 2012; 83: 260-267.
16. Brodin NP, Vogelius IR, Maraldo MV et al. Life years lost-comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale. Cancer 2012; 118: 5432-5440.
17. Gagliardi G, Constine LS, Moiseenko V et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 2010; 76: S77-S85.
18. Girinsky T, van der Maazen R, Specht L et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006; 79: 270-277.
19. Feng M, Moran JM, Koelling T et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys 2011; 79: 10-18.
20. Girinsky T, Pichenot C, Beaudre A et al. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 2006; 64: 218-226.
21. Maraldo MV, Brodin NP, Vogelius IR et al. Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2012; 83: 1232-1237.
22. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993; 270: 1949-1955.
23. Schellong G, Riepenhausen M, Bruch C et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer 2010; 55: 1145-1152.
24. Weber DC, Johanson S, Peguret N et al. Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage Hodgkin lymphoma in female patients. Int J Radiat Oncol Biol Phys 2011; 81: 490-497.